Pandemic & Infectious Disease — 2026-09-02
The CDC has released a new field report detailing the characteristics of the ongoing Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo. In vaccine news, Moderna’s mRNA flu vaccine received FDA approval following Phase 3 success, and GSK advanced its own mRNA flu candidate to Phase 3 trials. Respiratory illness levels remain very low in the US, though COVID-19 infections are growing in 48 states.
Pandemic & Infectious Disease — 2026-09-02
Active Outbreak Tracker
Ebola (Bundibugyo Virus) — Democratic Republic of the Congo
- Status: Ongoing outbreak
- Key Development: The CDC published a "Notes from the Field" report describing the characteristics and monitoring of the 2026 Ebola Disease outbreak caused by the Bundibugyo virus in the DRC.
- Response: CDC is monitoring the situation and providing updates on the current outbreak affecting DRC and Uganda.
CDC MMWR Report on Ebola
cdc.gov
Ebola Outbreak: Current Situation | Ebola | CDC
Current Epidemic Trends (Based on Rt) | CFA: Modeling and Forecasting | CDC
Respiratory Illnesses Data Channel | Respiratory Illnesses | CDC
Measles Cases and Outbreaks | Measles (Rubeola) | CDC
Cyclospora Case Data | Cyclosporiasis | CDC
Monkeypox in the United States and Around the World: Current Situation | Monkeypox | CDC
Respiratory Illnesses — United States
- Status: Very Low
- Key Development: As of August 28, 2026, the amount of acute respiratory illness causing people to seek health care is very low. However, modeling estimates suggest COVID-19 infections are growing or likely growing in 48 states.
- Response: CDC continues to provide data for COVID-19, flu, and RSV activity. Updates for flu and RSV will begin again in Fall 2026.
CDC Respiratory Illness Data Channel
cdc.gov
Ebola Outbreak: Current Situation | Ebola | CDC
Current Epidemic Trends (Based on Rt) | CFA: Modeling and Forecasting | CDC
Respiratory Illnesses Data Channel | Respiratory Illnesses | CDC
Measles Cases and Outbreaks | Measles (Rubeola) | CDC
Cyclospora Case Data | Cyclosporiasis | CDC
Monkeypox in the United States and Around the World: Current Situation | Monkeypox | CDC
Vaccine & Treatment Pipeline
-
mRNA Flu Vaccine (Moderna): The FDA approved Moderna’s mRNA flu vaccine after Phase 3 data showed improved efficacy compared with standard flu vaccines.
Moderna mRNA Flu Vaccine Approval -
XFG-adapted COVID-19 Vaccine (Pfizer and BioNTech): Received U.S. FDA approval for the 2026-2027 formula targeting the XFG variant. Shipping has begun to ensure rapid access to this season’s vaccine.
-
Investigational mRNA Seasonal Flu Vaccine (GSK): Advanced to a Phase 3 trial beginning in September 2026 after positive Phase 2 data showed stronger immune responses than licensed comparators. The candidate targets both hemagglutinin and neuraminidase.
GSK mRNA Flu Vaccine Candidate
Expert Analysis
No recent expert analysis or opinion pieces published within the last 24 hours were found in the provided search results.
Global Health Security
No recent policy developments, funding announcements, or preparedness initiatives published within the last 24 hours were found in the provided search results.
What to Watch Next
- GSK Phase 3 Trial Initiation: GSK's mRNA flu vaccine candidate enters Phase 3 in September 2026; early safety and efficacy data will be closely watched by infectious disease specialists.
- Fall Respiratory Season Onset: CDC will begin updating flu and RSV activity levels in Fall 2026, providing critical data on how the new XFG-adapted vaccines perform in the real world.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
